Santhera Pharmaceuticals Holding AG (SANN) — Cash Flow Quality Index

Latest as of December 2023: 0.80x

Santhera Pharmaceuticals Holding AG (SANN) has a Cash Flow Quality Index of 0.80x as of December 2023. Operating cash flow of CHF62.63 Million is below net income of CHF78.12 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow conversion of Santhera Pharmaceuticals Holding AG to assess how effectively this company generates cash.

Cash Flow Quality Index

0.80x
Operating CF / Net Income

Operating Cash Flow

CHF62.63 Million
CHF

Net Income

CHF78.12 Million
CHF

Data as of

Dec 2023
Most recent filing

Santhera Pharmaceuticals Holding AG Cash Flow Quality Index (2009–2023)

Historical Cash Flow Quality Index for Santhera Pharmaceuticals Holding AG across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Santhera Pharmaceuticals Holding AG (SANN) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Santhera Pharmaceuticals Holding AG (2009–2023)

Year-by-year earnings quality comparison for Santhera Pharmaceuticals Holding AG. For live market cap and the full company financial profile, see Santhera Pharmaceuticals Holding AG stock valuation.

Year Quality Index Operating CF (CHF) Net Income YoY Change
2023 0.86x CHF47.27 Million CHF54.78 Million ▲ +111.3%
2015 -7.63x CHF-22.39 Million CHF2.93 Million ▼ -853.2%
2009 -0.80x CHF-20.75 Million CHF25.92 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.